- Home
- SAFT vs SGP Comparison
SAFT vs SGP Comparison
Compare SAFT & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SAFT | SGP |
|---|---|---|
| Founded | 1979 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 932.9M |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | SAFT | SGP |
|---|---|---|
| Price | $77.78 | $23.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | ★ 70.6K | 67.1K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | ★ 4.81% | N/A |
| EPS Growth | ★ 40.17 | N/A |
| EPS | ★ 6.70 | N/A |
| Revenue | ★ $1,263,732,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.38 | ★ N/A |
| Revenue Growth | ★ 12.83 | N/A |
| 52 Week Low | $67.04 | $20.15 |
| 52 Week High | $84.20 | $30.56 |
Technical Indicators
Market Signals| Indicator | SAFT | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 62.76 | 42.13 |
| Support Level | $77.37 | $20.60 |
| Resistance Level | $77.88 | $26.55 |
| Average True Range (ATR) | 1.32 | 1.47 |
| MACD | 0.26 | 0.06 |
| Stochastic Oscillator | 95.31 | 43.21 |
Price Performance
Historical ComparisonAbout SAFT Safety Insurance Group Inc.
Safety Insurance Group Inc is a provider of private passenger automobile, commercial automobile, and homeowners insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. The company operates in the business segment of Property and casualty insurance operations.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.